Diabetes Mellitus, Type 2SURE FRANCENCT04083820
A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in France, as Part of Local Clinical Practice (SURE FRANCE)
An observational study of Diabetes Mellitus, Type 2, run by Novo Nordisk A/S at 53 sites in France.
Trial summary
The purpose of the study is to collect information on how semaglutide works in real world patients. Participants will get semaglutide prescribed by their study doctor. The study will last for about 6 to 8 months. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Diabetes Mellitus, Type 2
- What is being tested?
- semaglutide
- How many people
- 521 participants
- Where
- 53 sitesFrance
- Study dates
- 16 Sep 2019to 27 Sep 2021
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Participants with type 2 diabetes
Who may be able to join
- Signed informed consent obtained before any study-related activities (study-related activities are any procedures related to recording of data according to protocol)
- The decision to initiate treatment with commercially available semaglutide has been made by the patient/Legally Acceptable Representative and the treating physician before and independently from the decision to include the patient in this study
- Male or female, age greater than or equal to 18 years at the time of signing informed consent
- Diagnosed with type 2 diabetes at least 12 weeks prior to inclusion
- Available and documented haemoglobin A1c (HbA1c) value less than or equal to 12 weeks prior to initiation of semaglutide treatment
Who cannot join
- Previous participation in this study. Participation is defined as having given informed consent in this study
- Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation
- Treatment with any investigational drug within 90 days prior to enrolment into the study
- Hypersensitivity to semaglutide or to any of the excipients
Trial locations and contacts
53 sites in 1 country.
53 sites in 1 country
France53 sites
Novo Nordisk Investigational Site
Angers, 37540
Novo Nordisk Investigational Site
Annecy, 74600
Novo Nordisk Investigational Site
Auffay, 76720
Novo Nordisk Investigational Site
Avignon, 84902
Novo Nordisk Investigational Site
Besançon, 25000
Novo Nordisk Investigational Site
Bethoncourt, 25200
Novo Nordisk Investigational Site
Bèze, 21310
Novo Nordisk Investigational Site
Bourgoin, 38302
Novo Nordisk Investigational Site
Bry-sur-Marne, 94360
Novo Nordisk Investigational Site
Caen, 14033
Novo Nordisk Investigational Site
Challes-les-Eaux, 73190
Novo Nordisk Investigational Site
Chalon-sur-Saône, 71100
Novo Nordisk Investigational Site
Charleville-Mézières, 08000
Novo Nordisk Investigational Site
Chelles, 77500
Novo Nordisk Investigational Site
Clichy, 92110
Novo Nordisk Investigational Site
Colmar, 68000
Novo Nordisk Investigational Site
Colmar, 68024
Novo Nordisk Investigational Site
Dijon, 21000
Novo Nordisk Investigational Site
Dijon, 21079
Novo Nordisk Investigational Site
Dole, 39100
Novo Nordisk Investigational Site
Doudeville, 76560
Novo Nordisk Investigational Site
Élancourt, 78990
Novo Nordisk Investigational Site
Guiscard, 60640
Novo Nordisk Investigational Site
La Bouëxière, 35340
Novo Nordisk Investigational Site
La Madeleine, 59110
Novo Nordisk Investigational Site
Lambersart, 59130
Novo Nordisk Investigational Site
Le Puy-en-Velay, 43000
Novo Nordisk Investigational Site
Lomme, 59462
Novo Nordisk Investigational Site
Lyon, 69007
Novo Nordisk Investigational Site
Maison-Alfort, 94700
Novo Nordisk Investigational Site
Marseille, 13006
Novo Nordisk Investigational Site
Montélimar, 26200
Novo Nordisk Investigational Site
Montpellier, 34295
Novo Nordisk Investigational Site
Nevers, 58000
Novo Nordisk Investigational Site
Nice, 06202
Novo Nordisk Investigational Site
Noisy-le-Grand, 93160
Novo Nordisk Investigational Site
Orry-la-Ville, 60560
Novo Nordisk Investigational Site
Paris, 75010
Novo Nordisk Investigational Site
Paris, 75014
Novo Nordisk Investigational Site
Paris, 75877
Novo Nordisk Investigational Site
Pessac, 33600
Novo Nordisk Investigational Site
Pierre-Bénite, 69495
Novo Nordisk Investigational Site
Six-Fours-les-Plages, 83140
Novo Nordisk Investigational Site
Ste Foy Lès Lyon, 69110
Novo Nordisk Investigational Site
Strasbourg, 67000
Novo Nordisk Investigational Site
Toulouse, 31300
Novo Nordisk Investigational Site
Tours, 37000
Novo Nordisk Investigational Site
Valence, 26000
Novo Nordisk Investigational Site
Vénissieux, 69200
Novo Nordisk Investigational Site
Vichy, 03207
Novo Nordisk Investigational Site
Vienne, 38500
Novo Nordisk Investigational Site
Vitré, 35500
Novo Nordisk Investigational Site
Yerres, 91330
About this study
Official title: A Multi-centre, Prospective, Noninterventional Study Investigating the Effectiveness of Once-weekly Subcutaneous Semaglutide in a Real World Adult Population With Type 2 Diabetes
The purpose of the study is to collect information on how semaglutide works in real world patients. Participants will get semaglutide prescribed by their study doctor. The study will last for about 6 to 8 months. The participants will be asked to complete some questionnaires about their health and their diabetes treatment. Participants will complete these during their normally scheduled visits with their study doctor.
- Conditions
- Diabetes Mellitus, Type 2
- Being tested
- semaglutide
- Medical subject headings
- Diabetes Mellitus, Type 2
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
semaglutideDrug
Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.
| Study group | Role | What they receive |
|---|---|---|
| Semaglutide s.c. once-weekly | Participants will receive semaglutide at the treating physician's discretion as part of the usual clinical practice. The prescription and use of semaglutide is completely independent of this study. Total study duration for the individual patient will be approximately 30 weeks. Receives: Drug: semaglutide |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Glycated Haemoglobin A1c (HbA1c)
Measured in % point
Measured: Baseline (up to 12 weeks prior to treatment initiation (week 0) to end of study (week 28 to 38)
Change in Glycated Haemoglobin A1c (HbA1c)
Measured in mmol/mol
Measured: Baseline (up to 12 weeks prior to treatment initiation (week 0) to end of study (week 28 to 38)
Secondary outcomes (16)
Change in body weight
Measured in kg
Measured: Baseline (up to 12 weeks prior to treatment initiation (week 0) to end of study (week 28 to 38)
Change in body weight
Measured in %
Measured: Baseline (up to 12 weeks prior to treatment initiation (week 0) to end of study (week 28 to 38)
Change in waist circumference
Measured in cm
Measured: Baseline (up to 12 weeks prior to treatment initiation at week 0), end of study (week 28 to 38)
HbA1c level below 8.0% (64 mmol/mol) (yes/no)
Number of participants
Measured: At end of study (week 28 to 38)
HbA1c level below 7.5% (59 mmol/mol) (yes/no)
Number of participants
Measured: At end of study (week 28 to 38)
HbA1c level below 7.0% (53 mmol/mol) (yes/no)
Number of participants
Measured: At end of study (week 28 to 38)
Reduction in HbA1c of 1.0% point or more (yes/no)
Number of participants who achieved/not achieved reduction in HbA1c of 1.0% point or more
Measured: Baseline (up to 12 weeks prior to treatment initiation at week 0), end of study (week 28 to 38)
Weight reduction of 3.0% or more (yes/no)
Number of participants who achieved/not achieved weight reduction of 3.0% or more
Measured: Baseline (up to 12 weeks prior to treatment initiation at week 0), end of study (week 28 to 38)
Weight reduction of 5.0% or more (yes/no)
Number of participants who achieved/not achieved weight reduction of 5.0% or more
Measured: Baseline (up to 12 weeks prior to treatment initiation at week 0), end of study (week 28 to 38)
HbA1c reduction of 1.0% point or more and weight reduction of 3.0% or more (yes/no)
Number of participants who achieved/not achieved HbA1c reduction of 1.0% point or more and weight reduction of 3.0% or more
Measured: Baseline (up to 12 weeks prior to treatment initiation at week 0), end of study (week 28 to 38)
Patient reported severe or documented hypoglycaemia (yes/no)
Number of participants
Measured: Between baseline (week 0), end of study (week 28-38)
Change in score for Diabetes Treatment Satisfaction Questionnaire - Status (DTSQs) (absolute treatment satisfaction): Total treatment satisfaction
The status version (DTSQs) provides a measure of how satisfied patients are with their current diabetes treatment. It consists of 8 questions, which are to be answered on a Likert scale from 0 to 6 (0 = very dissatisfied to 6 = very satisfied). Six questions are summed to produce a total Treatment Satisfaction score. The remaining two questions are concerning perceived frequency of hyperglycaemia and perceived frequency of hypoglycaemia, respectively
Measured: Baseline (week 0), end of study (week 28 to 38)
Change in score for Diabetes Treatment Satisfaction Questionnaire - Change (DTSQc) (relative treatment satisfaction): Total treatment satisfaction
The change version (DTSQc) has the same 8 items as the status version, but is reworded to direct the patients to compare the experience of the current treatment with the experience of previous treatment. Each question is scored on a scale of -3 to +3 (-3 = much less satisfied now to +3 = much more satisfied now), with 0 (midpoint), representing no change
Measured: Baseline (week 0), end of study (week 28 to 38)
Change in score for Short Form (SF)-36 v2: Physical summary component
The SF-36®v2 questionnaire has 36 questions grouped into eight domains termed: physical functioning, bodily pain, role-physical, general health, vitality, social functioning, role-emotional and mental health, which again can be combined to give two summary component scores (overall mental- and physical health).
Measured: Baseline (week 0), end of study (week 28 to 38)
Change in score for SF-36 v2: Mental summary component
The SF-36®v2 questionnaire has 36 questions grouped into eight domains termed: physical functioning, bodily pain, role-physical, general health, vitality, social functioning, role-emotional and mental health, which again can be combined to give two summary component scores (overall mental- and physical health).
Measured: Baseline (week 0), end of study (week 28 to 38)
Patient completed the study under treatment with semaglutide (yes/no)
Number of participants
Measured: At end of study (week 28 to 38)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Sep 2019
- Study start16 Sep 2019
- Primary completion27 Sep 2021
- Study completion27 Sep 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Diabetes Mellitus, Type 2Studies of the same condition, open and under way.
- More trials run by Novo Nordisk A/SThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 521 participants (actual)
Sponsor and investigators
- Lead sponsor
- Novo Nordisk A/S
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Clinical Reporting Anchor and Disclosure (1452), Study director, Novo Nordisk A/S
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04083820
- Sponsor's protocol ID
- NN9535-4495
- Other IDs
- U1111-1222-5620
- Acronym
- SURE FRANCE
- Status last verified
- Mar 2023
- First submitted
- 6 Sep 2019
- Last updated
- 28 Mar 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Publications
Mohammedi K, Belhatem N, Berentzen TL, Catarig AM, Potier L. Once-weekly semaglutide use in patients with type 2 diabetes: Results from the SURE France multicentre, prospective, observational study. Diabetes Obes Metab. 2023 Jul;25(7):1855-1864. doi: 10.1111/dom.15045. Epub 2023 Mar 28.
PubMed 36869853
Study at a glance
From the registry record, last updated by the sponsor on 28 Mar 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Multi-centre, Prospective, Noninterventional Study Investigating the Effectiveness of Once-weekly Subcutaneous Semaglutide in a Real World Adult Population With Type 2 Diabetes
- ClinicalTrials.gov ID
- NCT04083820
- Acronym / sponsor ID
- SURE FRANCE / NN9535-4495
- Conditions
- Diabetes Mellitus, Type 2
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 521 participants (actual)
- Lead sponsor
- Novo Nordisk A/SIndustry (pharma, biotech, devices)
- Study start
- 16 Sep 2019 (actual)
- Primary completion
- 27 Sep 2021 (actual)
- Study completion
- 27 Sep 2021 (actual)
- First posted
- 10 Sep 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of the study is to collect information on how semaglutide works in real world patients. Participants will get semaglutide prescribed by their study doctor. The study will last for about 6 to 8 months. The participants will be asked to complete some questionnaires about their health and their diabetes treatment. Participants will complete these during their normally scheduled visits with their study doctor.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Semaglutide s.c. once-weekly | – | Drug: semaglutideParticipants will receive semaglutide at the treating physician's discretion as part of the usual clinical practice. The prescription and use of semaglutide is completely independent of this study. Total study duration for the individual patient will be approximately 30 weeks. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Participants with type 2 diabetes
Key inclusion criteria (5 listed)
- Signed informed consent obtained before any study-related activities (study-related activities are any procedures related to recording of data according to protocol)
- The decision to initiate treatment with commercially available semaglutide has been made by the patient/Legally Acceptable Representative and the treating physician before and independently from the decision to include the patient in this study
- Male or female, age greater than or equal to 18 years at the time of signing informed consent
- Diagnosed with type 2 diabetes at least 12 weeks prior to inclusion
- Available and documented haemoglobin A1c (HbA1c) value less than or equal to 12 weeks prior to initiation of semaglutide treatment
Key exclusion criteria (4 listed)
- Previous participation in this study. Participation is defined as having given informed consent in this study
- Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation
- Treatment with any investigational drug within 90 days prior to enrolment into the study
- Hypersensitivity to semaglutide or to any of the excipients
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| semaglutidePatients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion. | Drug | Semaglutide s.c. once-weekly |
Primary outcome
Change in Glycated Haemoglobin A1c (HbA1c)
Time frame: Baseline (up to 12 weeks prior to treatment initiation (week 0) to end of study (week 28 to 38)
Measured in % point
Change in Glycated Haemoglobin A1c (HbA1c)
Time frame: Baseline (up to 12 weeks prior to treatment initiation (week 0) to end of study (week 28 to 38)
Measured in mmol/mol
16 secondary outcomes
Change in body weight
Time frame: Baseline (up to 12 weeks prior to treatment initiation (week 0) to end of study (week 28 to 38)
Change in body weight
Time frame: Baseline (up to 12 weeks prior to treatment initiation (week 0) to end of study (week 28 to 38)
Change in waist circumference
Time frame: Baseline (up to 12 weeks prior to treatment initiation at week 0), end of study (week 28 to 38)
HbA1c level below 8.0% (64 mmol/mol) (yes/no)
Time frame: At end of study (week 28 to 38)
HbA1c level below 7.5% (59 mmol/mol) (yes/no)
Time frame: At end of study (week 28 to 38)
HbA1c level below 7.0% (53 mmol/mol) (yes/no)
Time frame: At end of study (week 28 to 38)
Reduction in HbA1c of 1.0% point or more (yes/no)
Time frame: Baseline (up to 12 weeks prior to treatment initiation at week 0), end of study (week 28 to 38)
Weight reduction of 3.0% or more (yes/no)
Time frame: Baseline (up to 12 weeks prior to treatment initiation at week 0), end of study (week 28 to 38)
Weight reduction of 5.0% or more (yes/no)
Time frame: Baseline (up to 12 weeks prior to treatment initiation at week 0), end of study (week 28 to 38)
HbA1c reduction of 1.0% point or more and weight reduction of 3.0% or more (yes/no)
Time frame: Baseline (up to 12 weeks prior to treatment initiation at week 0), end of study (week 28 to 38)
Patient reported severe or documented hypoglycaemia (yes/no)
Time frame: Between baseline (week 0), end of study (week 28-38)
Change in score for Diabetes Treatment Satisfaction Questionnaire - Status (DTSQs) (absolute treatment satisfaction): Total treatment satisfaction
Time frame: Baseline (week 0), end of study (week 28 to 38)
Change in score for Diabetes Treatment Satisfaction Questionnaire - Change (DTSQc) (relative treatment satisfaction): Total treatment satisfaction
Time frame: Baseline (week 0), end of study (week 28 to 38)
Change in score for Short Form (SF)-36 v2: Physical summary component
Time frame: Baseline (week 0), end of study (week 28 to 38)
Change in score for SF-36 v2: Mental summary component
Time frame: Baseline (week 0), end of study (week 28 to 38)
Patient completed the study under treatment with semaglutide (yes/no)
Time frame: At end of study (week 28 to 38)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Mar 2023.
- Background: PubMed 36869853Mohammedi K, Belhatem N, Berentzen TL, Catarig AM, Potier L. Once-weekly semaglutide use in patients with type 2 diabetes: Results from the SURE France multicentre, prospective, observational study. Diabetes Obes Metab. 2023 Jul;25(7):1855-1864. doi: 10.1111/dom.15045. Epub 2023 Mar 28.
- Individual participant dataSharing planned: Yes. According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Related trials for Diabetes Mellitus, Type 2
Not yet recruitingPhase 3
Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 Diabetes
Type 2 Diabetes
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Not yet recruitingPhase 3
A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 Diabetes
Obesity, Overweight
Not yet recruiting
Impact of Endoscopic Sleeve Gastroplasty (ESG) in Obese Adults With Type 2 Diabetes (T2D)
Type 2 Diabetes Mellitus (T2D), Obesity (BMI>30)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Clinical Reporting Anchor and Disclosure (1452) study director
Novo Nordisk A/S
53 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Diabetes Mellitus, Type 2, run by Novo Nordisk A/S at 53 sites in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 28 Mar 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 53 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Glycated Haemoglobin A1c (HbA1c) (time frame: Baseline (up to 12 weeks prior to treatment initiation (week 0) to end of study (week 28 to 38)). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04083820, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Mar 2023.